NCT04776824Recruiting
Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)
Source: ClinicalTrials.gov · Last updated 6 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Cardiac transthyretin amyloidosis (ATTR), caused by ventricular depositions of misfolded transthyretin, results in an infiltrative cardiomyopathy, progressing from pronounced myocardial wall thickening, diastolic and systolic dysfunction to the development of terminal heart failure. Recently, treatment options for TTR amyloidosis have become available. However costs for therapy are enormous and previous trials were not able to differentiate between patients that might benefit from treatment and those without a need for treatment. the investigators study aims to determine markers, as assessed by cardiac magnet resonance imaging (CMR) feature tracking (FT) and T1- and T2- mapping, that might reliably indicate disease severity and could help to identify patients that might benefit from (ongoing) TTR stabilization treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 25 Feb 2021
- Start date
- 22 Feb 2001
- Primary completion date
- 1 May 2031
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Diseases
- Amyloidosis
- NCT number
- NCT04776824
What you commit to
- Study type: Observational
- Planned participants: 300
- From 22 Feb 2001 to the primary completion date, 1 May 2031
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Inability to give consent or existence of a written or documented oral refusal of the data subject.\<18 years of age
Who the study is looking for
- Confirmed diagnosis of amyloidosis w/wo cardiac involvement
- General Consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| USB Coordinator of this site? Confirm its status | Basel | Switzerland | Not yet recruiting |
| Department of Cardiology, University Hospital Bern, Inselspital, Bern Coordinator of this site? Confirm its status | Bern | Switzerland | Recruiting |
| HUG Coordinator of this site? Confirm its status | Geneva | Switzerland | Recruiting |
| CHUV Coordinator of this site? Confirm its status | Lausanne | Switzerland | Recruiting |
| LUKS Coordinator of this site? Confirm its status | Lucerne | Switzerland | Recruiting |
| KSSG Coordinator of this site? Confirm its status | Sankt Gallen | Switzerland | Recruiting |
| Stadtspital Triemli Coordinator of this site? Confirm its status | Zurich | Switzerland | Recruiting |
Related publications
- Indication and electrical performance of conventional, resynchronization, and conduction system pacing in transthyretin amyloid cardiomyopathy.Heart Rhythm O2 · 2026 · PMID 42488169
- Correlation of global and regional quantitative 99m Tc-3,3-diphosphono-1,2 propanodicarboxylicacid single-photon emission computed tomography with echocardiography in patients with suspected transthyretin-related cardiomyopathy.Nucl Med Commun · 2026 · PMID 41804669
This page is information, not medical advice. Discuss any trial with your doctor.